The Controversy Over Ponatinib
Although ponatinib was given accelerated approval by the FDA, it was withdrawn based on evidence of serious thrombotic adverse events.
{{{error}}}
{{error}}
{{{ form.title }}}
*Required
{{{field.value}}}
{{{field.value}}}
{{{field.value}}}
